TARS — Tarsus Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1819790 ·
Last close
$78.20
Market Cap
$3.86B
52W High
$91.53
52W Low
$53.89
ADV30
959,142
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 194,569,000 | 180,675,000 | -663,714,000 | -668,334,000 | 505,499,000 | 136,530,000 | 401,470,000 |
| Jun 2026 | 173,912,000 | 161,799,000 | -19,908,000 | -18,551,000 | 611,142,000 | 204,595,000 | 264,410,000 |
| Mar 2026 | 162,054,000 | 152,658,000 | -6,122,000 | -6,967,000 | 581,135,000 | 102,192,000 | 232,184,000 |
| Dec 2025 | 151,668,000 | 140,741,000 | -7,976,000 | -8,373,000 | 562,158,000 | 183,641,000 | 218,732,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$49,899,000
Investing CF
$-160,901,000
Financing CF
$134,627,000
CapEx
$-54,748,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.19
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,120,480,000
Inventory
$5,159,000
Receivables
$102,106,000
ST Investments
$173,082,000
EBIT TTM
$-682,425,000
Pretax Income TTM
$-690,456,000
Interest Exp TTM
$8,031,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$682,203,008
EBITDA
$-62,637,000
Free Cash Flow
$79,938,128
Enterprise Value
$3,162,180,864
Total Cash
$309,612,000
Total Debt
$89,432,000
Shares Out
49,305,552
Trailing EPS
$-15.86
Book Value
$2.11
ROE
-319.8%
ROA
-7.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 451,360,000 | -70,969,000 | -66,418,000 | 562,158,000 | 218,732,000 | 343,426,000 | -12,451,000 |
| Dec 2024 | 182,953,000 | -120,569,000 | -115,554,000 | 376,991,000 | 152,457,000 | 224,534,000 | -83,027,000 |
| Dec 2023 | 17,447,000 | -143,158,000 | -135,893,000 | 265,491,000 | 68,503,000 | 196,988,000 | -117,493,000 |
| Dec 2022 | 25,816,000 | -62,712,000 | -62,091,000 | 227,863,000 | 34,963,000 | 192,900,000 | -49,030,000 |
TTM Snapshot
Revenues TTM
$606,331,000
NetIncome TTM
$-46,476,000
OpCashFlow TTM
—
Assets (Latest)
$611,142,000
Forward EPS
$0.21
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $67.50 · spot: $75.95 · call volume: 218 · put volume: 23Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG | $3.89B | $40.15 | — |
| RLAY | Relay Therapeutics, Inc. | $3.64B | $16.47 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $3.48B | $7.53 | — |
| ADPT | Adaptive Biotechnologies Corp | $4.61B | $28.49 | — |
| ADMA | ADMA BIOLOGICS, INC. | $3.02B | $13.63 | — |
News headlines (Yahoo Finance, 1h cache)
Is Raised Revenue Outlook Altering The Investment Case For Tarsus Pharmaceuticals (TARS)?
2026-11-06 14:11 · Yahoo
Is Tarsus Pharmaceuticals (TARS) Below Fair Value On Cash Flow?
2026-11-06 06:10 · Yahoo
Tarsus Pharmaceuticals (TARS) Could Be 31% Undervalued Following Record Q3 Sales
2026-11-05 22:09 · Yahoo
Tarsus to Participate in Upcoming Investor Conferences
2026-11-05 21:30 · Yahoo
Tarsus Pharmaceuticals Inc (TARS) (Q3 2026) Earnings Call Highlights: Record Xtendi Sales and ...
2026-11-05 03:04 · Yahoo
Tarsus (TARS) Q3 2026 Earnings Call Transcript
2026-11-04 16:16 · Yahoo
Tarsus Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Tarsus Pharmaceuticals Q3 Earnings Call Highlights
2026-11-04 03:14 · Yahoo
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
2026-11-03 23:55 · Yahoo
Tarsus Reports Third Quarter 2026 Financial Results
2026-11-03 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.